US Cryptococcosis Therapeutics Market Report 2023 to 2030

US Cryptococcosis Therapeutics Market Analysis

$ 3999

US Cryptococcosis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The pathogenic yeasts in the genus Cryptococcus that cause cryptococcosis have a wide range of clinical manifestations and are contagious throughout the world. Currently, Cryptococcus neoformans and Cryptococcus gattii are the two species of the bacteria most frequently linked to human illness. The market for disorders caused by cryptococcosis is expanding as a result of the rising prevalence of the condition and the availability of cutting-edge treatments. Bristol-Myers Squibb, Abbott Laboratories, Pfizer, Glenmark Pharmaceuticals, Bausch Health, Johnson & Johnson, Novartis AG, Janssen Biotech, Sigmapharm Laboratories, Matinas BioPharma, Mycovia Pharmaceuticals, Aparna Biosciences, FUJIFILM Toyama Chemical, TGV Therapeutics, Amplyx Pharmaceuticals, and many others are leading companies in the global market for Cryptococcosis therapeutics.

ID: IN10USRD017 CATEGORY: Rare Diseases GEOGRAPHY: US AUTHOR: Nipun Arora

Buy Now

US Cryptococcosis Therapeutics Market Analysis Summary

US Cryptococcosis Therapeutics Market is valued at around $2.33 Bn in 2022 and is projected to reach $3.47 Bn by 2030, exhibiting a CAGR of 5.1% during the forecast period 2023-2030.

The pathogenic yeasts in the genus Cryptococcus that cause cryptococcosis have a wide range of clinical manifestations and are contagious throughout the world. Currently, Cryptococcus neoformans and Cryptococcus gattii are the two species of bacteria most frequently linked to human illness. Inhaling dust that contains yeast cells can cause cryptococcosis, which typically affects the lungs. Fever, malaise, cough, hemoptysis (bloody or blood-tinged sputum), headache, and vision abnormalities (blurry or double vision, photophobia) are only a few of the symptoms of cryptococcosis. By employing Indian ink and direct microscopic examination, it is possible to detect yeasts encapsulated in cerebrospinal fluid (CSF) and make the diagnosis of cryptococcosis in 95% of cases. Urine collection, a chest x-ray, and a lumbar puncture come first.

C. neoformans have a distinct culture. Blood cultures may be positive, especially in people with AIDS, but CSF, sputum, and urine are the most often produced bodily fluids. In cases of cryptococcal meningitis, elevated CSF protein and a pleocytosis of mononuclear cells are common. Low glucose levels are common. In CSF or blood samples, or both, the latex test for cryptococcal capsular antigen is positive.

The market for disorders caused by cryptococcosis is expanding as a result of the rising prevalence of the condition and the availability of cutting-edge treatments. Bristol-Myers Squibb, Abbott Laboratories, Pfizer, Glenmark Pharmaceuticals, Bausch Health, Johnson & Johnson, Novartis AG, Janssen Biotech, Sigmapharm Laboratories, Matinas BioPharma, Mycovia Pharmaceuticals, Aparna Biosciences, FUJIFILM Toyama Chemical, TGV Therapeutics, Amplyx Pharmaceuticals, and many others are leading companies in the global market for Cryptococcosis therapeutics.

Market dynamics

Market Drivers

HIV cases: According to the Centers for Disease Control and Prevention and the World Health Organization, 220,000 cases of cryptococcal meningitis are thought to occur worldwide each year among people with HIV/AIDS, leading to close to 181,000 fatalities.

Technology development: The main reasons driving the growth of the market for cryptococcosis disorders are the rising prevalence of the disease and the availability of cutting-edge treatments.

Developments in the Cryptococcosis Therapeutics market

Matinas BioPharma, MAT 2203 Amphotericin B, a broad-spectrum fungicidal drug, is formulated as MAT2203, an oral medication that uses Matinas' own lipid nano-crystal ("LNC") delivery technology platform. By encapsulating tiny molecules, nucleic acid polymers like oligonucleotides, vaccines, peptides, proteins, and other medications, the company's LNC delivery technology may make them safer, more acceptable, less toxic, and orally bioavailable.

Restraints in US Cryptococcosis Therapeutics market

When patents expire, generic companies are invited to enter the market, which serves to constrain the Cryptococcosis Therapeutics Market.

Key players

AbbVie Astellas Pharma Inc. Gilead Sciences Janssen Pharmaceuticals Merck & Co., Inc. Novartis AG Pfizer Inc. Roche Holding AG Sanofi Theratechnologies, Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market segmentations for US Cryptococcosis Therapeutics market

By Treatment

Polyenes- amphotericin B and nystatin
Triazoles- voriconazole and itraconazole
Nucleoside drugs- 5-fluorocytosine

By End User

Hospital Pharmacies
Retail Pharmacies
Drug Store
Other

By route of administration

Oral
Parenteral
Intravenous
Subcutaneous
Topical

By molecule type

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.